Clinical Trials

Putting the Patient First: Not Just When It’s Convenient

Introduction Successful clinical trials rely on effective patient recruitment and retention. However, a 2019 report indicates that the industry continues to struggle meeting these objectives. The study found that about 80 percent of clinical trials don’t meet patient enrollment deadlines,...

CluePoints Central Statistical Monitoring Supports Business Continuity as Coronavirus Impacts Clinical Trial Operations

CluePoints, the premier provider of Risk-Based Trial Execution (RBx) and Data Quality Oversight Software for clinical trials, announced that it has seen a dramatic increase in demand for remote and centralized site monitoring amid the ongoing Coronavirus outbreak. With...

Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement

Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody. As part of the...

Clinerion received ISO 27001:2013 certification

Clinerion has gained ISO 27001:2013 certification, the international standard that describes best practice for an information security management system (ISMS). ISO 27001:2013 is a standard set by the International Organization for Standardization (ISO), the independent, non-governmental international organization of national...

The unexpected benefits of clinical trial disclosure

Introduction: Patients, clinical trial sponsors and institutions are starting to benefit from increased transparency commitments and significant investments in trial data disclosure. To make an ever-broader scope of trial data public, leading pharmaceutical organizations have been refining their processes and...

Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension

Bellerophon Therapeutics, Inc , a clinical-stage biotherapeutics company, announced the successful completion of its End-of-Phase 2 Meetings with the U.S. FDA for INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF). The Company, in consultation with the...

Clinerion and iClusion partner to boost the identification and recruitment of more patients into clinical trials

Clinerion’s Patient Network Explorer and iClusion’s Trial Eye platforms both connect clinical trial sponsors with networks of partner hospitals, giving trial managers the ability to include eligible patients for trials more quickly and efficiently than before. Treating physicians and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read